title: Impact of different hold time before addition of platelet additive solution on the in vitro quality of apheresis platelets.
abstract: BACKGROUND
  The quality of platelets (PLTs) stored in PLT additive solution (PAS) is dependent on the type and proportion of the used PAS. No data are available as to whether a different hold time before the addition of PAS to hyperconcentrated PLT suspensions has an impact on PLT quality. The in vitro quality between single-donor PLT concentrates was compared with two different hold times with two PASs.
  
  
  METHODS
  On two occasions, 6x10(11) PLTs in 150 mL of plasma were collected from 20 blood donors. The units were split into two equal parts, and 140 mL of PAS-II or PAS-IIIM (randomized sequence) was added after 2 or 8 hours resulting in a PAS proportion of 65 percent. On Days 1, 5, and 7, glucose and lactate concentration, pH value, PLTs' P-selectin expression, response to hypotonic shock, and release of transforming growth factor-beta1 were determined.
  
  
  RESULTS
  On all days, the lactate concentrations were higher and pH values were lower in units with an 8-hour hold time, whereas the results of in vitro tests relating to the in vivo viability and activation of PLTs were similar for both groups. PAS-IIIM-stored PLTs showed a lower glycolytic activity and better results in all performed in vitro tests than PAS-II-stored PLTs.
  
  
  CONCLUSIONS
  Although the metabolism of glucose was enhanced during hold time, the differences between both hold time groups are not meaningful from a biological viewpoint. Therefore, an 8-hour hold time is feasible. PLT storage in PAS-IIIM results in a PLT in vitro quality superior to that of PLTs stored in PAS-II.
authors.affiliation: Department for Transfusion Medicine and Haemostaseology, University Hospital of Erlangen, Erlangen, Germany. Juergen.Ringwald@trans.imed.uni-erlangen.de
authors.forename: Jürgen
authors.initials: J
authors.lastname: Ringwald
authors.forename: Benedikt
authors.initials: B
authors.lastname: Haager
authors.forename: Daniel
authors.initials: D
authors.lastname: Krex
authors.forename: Robert
authors.initials: R
authors.lastname: Zimmermann
authors.forename: Erwin
authors.initials: E
authors.lastname: Strasser
authors.forename: Marc
authors.initials: M
authors.lastname: Antoon
authors.forename: Eddy
authors.initials: E
authors.lastname: De Schrijver
authors.forename: Reinhold
authors.initials: R
authors.lastname: Eckstein
mesh_terms: D001792:Blood Platelets / Q000187:drug effects*; D001793:Blood Preservation / Q000379:methods*; D005947:Glucose / Q000378:metabolism; D006801:Humans; D006863:Hydrogen-Ion Concentration; D019344:Lactic Acid / Q000032:analysis; D009997:Osmotic Pressure; D019007:P-Selectin / Q000032:analysis; D010983:Plateletpheresis / Q000592:standards*; D012996:Solutions / Q000494:pharmacology*; D013997:Time Factors; D016212:Transforming Growth Factor beta / Q000032:analysis; D053773:Transforming Growth Factor beta1
chemical_list: D019007:P-Selectin; D012996:Solutions; C508960:TGFB1 protein, human; D016212:Transforming Growth Factor beta; D053773:Transforming Growth Factor beta1; D019344:Lactic Acid; D005947:Glucose